Home Alzheimer’s Disease Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA...

Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial

Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with stage IB–IIIA EGFR mutation positive non-small cell lung cancer, at the 2020 ASCO Virtual Scientific Program.

Transcription:

My key takeaway is that biologic therapy works in lung cancer just like it worked in breast cancer 15 years ago with receptive [therapy]. You take the biology of the tumor; you give a targeted agent that can be given for long periods of time—in this case 3 years—you see that you prevent the disease from recurring. As we prevent the disease from metastasizing or spreading, that’s going to improve outcome. There won’t be disease popping up in the brain, the liver, the bone at the same extent. Here, 83% less likely. That, of course, is great for patients because they…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Recent Comments